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Abstract 
This report reviews the case of a 62-year-old female experiencing a delusional disorder 
(DD), persecutory type with bipolar I disorder in partial remission.  Various studies describe the 
challenges associated with treating a DD and evidence is mixed.  Evidence on etiology, current 
and future treatment, and treatment challenges were appraised from 30 articles.  Methods of 
research included placebo studies, clinical trials, survey questionnaires, retrospective, and 
prospective methods.  Research design methods involved controlled single-blind procedures, 
systematic reviews, expert opinions, case studies, and randomized control trials.  Although DD is 
not well understood, positive outcomes have been noted when patients are treated with a 
combination of medication, cognitive behavioral therapy, and behavioral learning techniques.  
High quality research on treatment guidelines are needed to improve understanding among 
clinicians and patients.   
 Key words:  Delusional disorder, persecutory delusions, treatment challenges of 
delusional disorder 
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Background 
People with DD, persecutory type believe they have been or will be harmed, persecuted, 
or conspired against.  Actions are taken to protect themselves against the actions of the suspected 
source, sometimes resorting to violence and requiring hospitalization (Tamminga, 2018).  The 
etiology is unknown, but factors such as perception of threat, fatigue, emotional stress, and 
reasoning biases may contribute as well as a genetic predisposition to a selective D2 receptor-
related hyper-dopaminergia and dopamine dysfunction (Manschreck, Marder, & Hermann, 
2018). 
Approximately 20% to 30% of people in the general population have thoughts of 
paranoia on a regular basis.  Only 10% of these individuals will hold on to a delusion despite a 
contrary reality.  Lifetime prevalence in the general population is approximately 0.2% with onset 
occurring in middle to late adulthood.  Forty-eight percent of people with a delusion disorder 
have the persecutory type and they are also likely to have a mood disorder (major depression and 
bipolar disorder) (Manschreck et al., 2018; Vicens, Sarro, & McKenna, 2014). 
Current treatments frequently use antipsychotics, antidepressants, and mood stabilizers. 
Cognitive behavioral therapy (CBT) and psychotherapy have also been shown to be helpful 
(Skelton, Khokhar, & Thacker, 2015).  However, high quality evidence for treatment of the 
disorder is lacking and there are no treatment guidelines, rendering it quite difficult to treat.  This 
paper will explore current evidence about the etiology, treatment strategies, and challenges of 
treating a DD.   
Case report 
P.J. presented to an emergency room after police found her driving on the opposite side 
of the road, forcing several cars off the road.  Police described her as not being reality-based and 
TREATMENT CHALLENGES OF DELUSIONAL DISORDERS  5 
 
aggressive by pulling out a knife.  When police asked her why she had been driving on the 
wrong side of the road, she stated, “God told me they were boy scouts that needed to be killed.”   
She required restraints and injections when presenting to the emergency room.  Staff 
reported she made references to God speaking to her and having a beautiful mind with a gift for 
extrasensory perception (ESP).   She lacked insight into her symptoms and was subsequently 
hospitalized for three weeks in an inpatient psychiatric unit during which she refused to take any 
medications.  Unwilling to engage in treatment, she was admitted to a behavioral health hospital 
in the community for treatment.   
When meeting with P. J. on admission, she presented as grandiose, pleasant, euphoric, 
irritable at times with pressured speech, and deterred from answering specific questions about 
events leading up to her hospitalizations.  She held elaborate beliefs about the CIA and homeland 
security following her and falsifying all police reports that involved incidents related her mental 
illness.  Her county case manager and husband were also part of this elaborate plan to ensure she 
was wrongly hospitalized for a non-existent mental illness.  Her husband’s motive for enabling 
her forced hospitalization and county commitment was an attempt to cover up his “abusive 
ways” during their 40+ years of marriage.   
When asked why she was driving on the wrong side of the road she denied this and stated 
she was looking for friends on the side of the road who were in need of help.  In her mind, she 
never put anyone in harm’s way. Rather, she insisted she was giving bystanders on the road the 
“boy-scout sign” and wishing them well. She denied trying to run cars off the road, talking to 
God, hearing God talk to her, or pulling out a knife on others and insisted these were false 
allegations created against her. Furthermore, she verbalized stealth readiness to fight a proposed 
Jarvis order that would mandate she receive treatment with neuroleptic medication(s).  
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P.J. reported having a previous manic episode two years ago that required hospitalization.  
She endorsed having a bipolar I disorder but attributed this to black mold exposure after 
remodeling her basement.  She stated she hadn’t slept for seven days and was “getting too 
carried away with trying to track down ISIS on the internet”.  During that hospitalization, she 
reported experiencing some benefit from oral Risperdal, but when they discharged her on 5mg, 
she felt as though it “zombified” her.  Her primary care provider tapered her off Risperdal over 
the course of a year after she reported having transient chest pain from the medication.  
PJ’s medical history, health and physical exam, labs, Lyme’s screen, CT scan were 
insignificant. There was little to no history of problems with alcohol or a substance use problem.  
Her father died three years ago of cancer and had a history of a suicide attempt.  Family history 
of mental illness is not clear other than her family having a reputation for being excessively 
dedicated to work and education pursuits. Her case worker reported P.J. did well when she took 
Risperdal and was a completely different person.   
Throughout the course of her hospital stay, her insight remained poor. Treatment plan 
meetings entailed her vehemently disagreeing with all aspects of her diagnosis and treatment.  
She was frequently accusatory to the treatment team and anyone who supported treatment. She 
trusted only people who she perceived to be anti- medication: her primary care provider and a 
former psychiatrist who has a popular anti-psychiatry internet blog in Minnesota.    
A Jarvis order was eventually granted for four different antipsychotic medications.  She 
begrudgingly agreed to take a daily oral dose of Risperdal 1.5mg.  She was very distressed by 
this and requested high doses of aspirin as needed to “cancel out the Risperdal”.  Treatment 
recommendations were to continue to increase the Risperdal for resolution of symptoms. 
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However, she demonstrated extreme of distress at the thought of increasing the dose more than 
1.5mg and believed other medications would be worse than Risperdal.   
Toward the end of her hospital stay, there was some improvement in P.J.’s symptoms, i.e. 
slightly less grandiose and guarded.  Interactions with her were less intense and her husband 
reported they were able to communicate better.  However, low insight persisted with a desire to 
manage the “bipolar disorder” non-medicinally when the Jarvis order expires.  Total denial of a 
DD ensued. 
Aftercare plans for P.J. included follow-up with her primary care provider as he was in 
agreement and understanding of the Jarvis and Commitment processes.  P.J. also had plans of 
regularly attending a bipolar disorder support group in her area.  Two weeks post-discharge, she 
and her husband were doing well at home.    
Her initial diagnosis was Bipolar I Disorder with psychotic features versus 
schizoaffective disorder, bipolar type.  She displayed some symptoms of mania or hypomania 
(some grandiosity, irritability, and pressured speech), but did not meet criteria for a full manic 
episode.  She showed no evidence of experiencing a depressive episode.   
Schizoaffective disorder was ruled out because she did not meet Criteria A for 
schizophrenia (disorganized speech, catatonic or grossly disorganized behavior, or negative 
symptoms) (APA, 2013; Shea, 2017).  DD, persecutory type for longer than one month was 
fitting as her level of daily functioning was not significantly impaired.  Also, the persecutory 
thoughts occurred in the absence of a manic or depressive episode.  Possible medical conditions, 
medications, or substances that may have contributed to her delusional thinking were also ruled 
out (First, 2014).  Therefore, her diagnosis was concluded to be bipolar I disorder, in partial 
remission with the primary diagnosis being DD, persecutory type.   
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Literature Review 
Definition 
DD is the least disabling of the schizophrenia spectrum disorders.  It is a thought disorder 
that often goes unrecognized and is based on faulty cognition.  Interestingly, the delusion does 
not typically interfere with daily functioning and people tend to appear to lead normal lives.  
Rarely do they come to the attention of needing psychiatric services.  Those who do present with 
the need for services are likely to be in great conflict with those around them due to their 
elaborate beliefs (Fear, 2013).   
Type 
Persecutory delusions were originally distinguished from other types of delusions and 
melancholia by Lasegue (Semelaigne, 1894).  It is the most common type of delusion that can 
occur and can involve the inanimate or animate, people or machines, systems, organizations, 
institutions, or a vague influence (Kiren & Chaudhury, 2009; Reichenberg & Seligman, 2016).  
When a person feels slighted, resulting feelings lead to the development of a delusional system 
that includes a fear of being watched or followed, poisoned, cheated on, or conspired against 
(Reichenberg et al., 2016).  It often persists despite evidence to the contrary (Kiren et al., 2009). 
Complications 
Beliefs of persecution can cause suicidal or homicidal ideation and sometimes escalate to 
violence or lawsuits (Reichenberg et al., 2016). Suicidal behavior occurs between eight  
and twenty-one percent of the time in DD and is more prevalent among the persecutory type of 
DD.  The ideations and degree of past and present impulsivity should be assessed carefully.  
Attempts should be made to understand how the patient previously coped with the persecutory 
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beliefs in order to determine degree of risk (Gonzalez-Rodriguez et al., 2014a; Manschreck et al., 
2018).     
Diagnostic Criteria  
According to the American Psychiatric Association (2013), diagnostic criteria for DD 
involves the presence of one or more delusions that last one month or longer and does not meet 
criteria A for schizophrenia.  Daily functioning is not significantly impaired, the delusion does 
not occur during a mood episode, and the delusion is not attributable to a medical condition, 
substance, or medication (First, 2014).   
There are seven types of delusions with or without bizarre content: erotomanic, 
grandiose, jealous, persecutory, somatic, mixed, and unspecified (APA, 2013).  Persecutory 
delusions are commonly seen as part of a psychotic process in other disorders such as bipolar 
disorder, schizophrenia, psychotic depression, and substance-induced states (Shea, 2017).   
Medical causes should be ruled out particularly for persons over the age of 40.  Various 
medical conditions include endocrine disorders, brain tumors, delirium, malignant gliomas, 
infections, and temporal lobe epilepsy are some.  Dementia should also be considered due to 
20% of patients with Alzheimer’s presenting with paranoid delusions.  However, this tends to 
occur later in the disease process (Manschreck et al., 2018).     
Prognosis 
Delusional course varies and involves brief or fleeting states that spontaneously remit 
while other respond to standard treatment.  Conversely, others continue to develop elaborate 
beliefs into a comprehensive and complex system that can remain unchanged with regular 
medication (Kiren et al., 2009).  Persons with persecutory, erotomanic, and somatic delusions 
tend to recover quickly and have a better prognosis than patients with grandiose and jealous 
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types.  Delusions that were brief in duration with a rapid onset among patients who were 
functioning well have better prognosis (Shea, 2017).  Remission has been reported to have 
occurred in one third of cases, rendering two thirds to be life-long with continuous or periodic 
delusions (Manschreck et al., 2018). 
Causes 
Paranoia severity exists on a spectrum with the severest form being persecutory 
delusions, i.e. threat beliefs and are thought to have developed as a result of environment, 
genetics, and psychological factors.  At the core of the persecutory beliefs is that others seek to 
deliberately inflict harm.  Maintenance of this thought process includes worry, negative self-
beliefs, anomalous experiences, sleep dysfunction, reasoning bias, and safety behaviors 
(Freeman, 2016). 
Biological 
Neurobiological theories involve dysfunction in the thalamus, basal ganglia, septo-
hippocampal region of the brain, semantic memory, hypometabolism in the prefrontal and 
anterior cingulate regions, and hyperactivation of the cingulate gyrus and right inferior parietal 
lobule (Kiren et al., 2009). Patients with DD may have abnormalities in the brain such a 
reduction in grey matter in the bilateral insula and medial frontal/anterior cingulate cortex 
(Vicens et al., 2016).  Other studies have shown grey matter reduction in the striatal and thalamic 
regions (Wolf et al., 2014).     
There is evidence of a relationship between delusions and elevated perfusion and 
overactivity of the hippocampus. The hippocampus plays an important role in retrieving 
contextual information.  Overactivity causes a misinterpretation of incoming stimuli and can lead 
to delusional beliefs. In turn, this can cause an abnormal neurotransmission of dopamine in the 
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striatum and ventral tegmental area.  Overtime, it is suggested that elevated perfusion in the 
striatum could cause an increase in distressing symptoms and on-going evolution of illness 
(Wolthusen et al., 2017).   
Kondo et al. (2013) suggests that 5-HT3A receptors play a role in DDs and are 
responsible for the extinction of tone-cued and contextual fear.  5-HT3A has been suggested to 
play a role in the expression of neurons in limbic regions of the brain such as the cortex, 
amygdala, and hippocampus and subsequently plays a role in spatial learning, memory, social 
behavior, and anxiety-like behavior (Kondo et al., 2013).   
Adversity and Trauma 
Adversity may also play a role with one’s degree of persecutory ideation.  Valiente et al. 
(2017) found an association between high levels of paranoia and adversity experiences that lead 
to experiential avoidance.  Furthermore, negative beliefs about others and self and dysfunctional 
strategies of regulation of self-esteem are suspected to have some level of connection to 
persecutory thinking.  
Interestingly, genetic research evidence suggests the dopamine D1 receptor gene does not 
necessarily play a role in DDs (Fear, 2013).  Scott, Chant, Andrews, and McGrath (2007) found 
that an increase in delusional experiences can occur after exposure to a traumatic event if post-
traumatic stress disorder (PTSD) does not develop.  There is some evidence of a relationship 
between endorsement of delusional experiences and the number and intensity of traumatic event 
experiences (Calvert, Larkin, & Jellicoe-Jones, 2008; Scott et al., 2007).   
Psychological compensatory mechanisms 
Delusional beliefs may serve as a psychological compensation for life disappointments 
such as when they feel taken advantage of, mistrustful, isolated, helpless or stressed.  People 
TREATMENT CHALLENGES OF DELUSIONAL DISORDERS  12 
 
with the disorder can be defensive, quarrelsome, or moody.  Others may be grandiose and 
believe they have special knowledge or are successful in order to increase self-esteem (Shea, 
2017). 
Psychological theories associated with the development of DDs include stress and 
vulnerability, personality, attributional bias, probabilistic reasoning bias, emotions and 
perception, mind (paranoid syndromes), psychodynamic (Freud’s posit of denial and projection 
of repressed impulses), explanations of experience, and learning based on fear (Kiren et al., 
2009).  Faulty cognitions and maladaptive coping can lead to DDs and include having an 
attributional bias where others are blamed instead of themselves, jumping to conclusions without 
evidence, confirmation bias in which the person seeks proof to confirm their beliefs, reaction 
formation, and projection (Reichenberg et al., 2016; Shea, 2017).   Psychological factors include 
low self-confidence, excessive worry, reasoning biases, safety-seeking strategies, intolerance of 
anxious emotions, and various anomalous factors (Freeman, 2016; Kiren et al., 2009).   
Subtle cognitive impairments have been noted in some studies in which 
neuropsychological assessment found dysfunction in working memory, clear impairment in 
executive functioning and memory, changes in personality, and social cognition deficits 
(Manschreck et al., 2018).  Negative cognition and depressed mood are frequently associated 
with paranoid ideation.  Ideas about the self that are negative appear to determine the strength of 
delusional thoughts of persecution (Davis & Gaurava, 2015).    
Current Treatments 
Psychopharmacotherapy 
Establishing a therapeutic relationship with the patient is crucial.  Preventing and 
managing complications of the disorder is also an important part of treatment.  If the patient 
becomes dangerous to self or others, hospitalization may be indicated.  Medication can be 
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helpful with the long-term goal of ensuring the patient focuses on constructive and gratifying 
areas of their life and shift away from the delusional content, if possible (Tamminga, 2018).   
Medication management of symptoms demonstrate a 50% positive response rate to 
antipsychotics.  Antipsychotics have antagonist effects on neurotransmitters, glutamate and 
dopamine, specifically (Skelton, 2015; Stahl, 2013).  A systematic review of case series and 
observational studies found that antipsychotics achieved good response rates among 33.6% of 
385 patients.  First generation antipsychotics showed significantly better outcomes compared to 
second generation antipsychotics.  However, no specific antipsychotic more superior than the 
other (Kulkarni et al., 2017; Munoz-Negro & Cervilla, 2016).   
Pimozide, risperidone, olanzapine, and ziprasidone have been shown to be effective, 
particularly when diagnosis occurs early (Kulkarni et al., 2017; Shea, 2017).  Prospective data 
demonstrated successful treatment with risperidone among patients with paranoid schizophrenia. 
Risperidone (or Risperdal) has shown to play a role in the 5-HT3 gene and is thought to increase 
5-HT3A receptor gene expression.  5-HT3A regulates the release of dopamine, gamma-
aminobutyric acid (GABA), and acetylcholine (Chen et al., 2017; Kondo et al., 2013).   
A case report by Davis et al. (2015) discussed successful treatment with Lurasidone as a 
monotherapy for a patient with a DD, persecutory type.  Within 10 days of treatment, the 
patient’s delusions fully remitted, and insight improved.  Progress was maintained seven months 
post-discharge (Davis et al., 2015). 
DDs have been being linked to a pathology of an obsessive attention and obsessive-
compulsive disorder (OCD).  Id’ees fixes or a desire that dominates the mind is a 19th century 
belief that there is a pathology of attention underlying the disorder. Evidence shows that high 
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doses of SSRIs are effective for OCD and some evidence has shown them to be also helpful for 
DD (Fear, 2013).   
As preoccupation with the delusion decreases, depression and anxiety may increase due 
having been previously masked.  It is important to assess and treat arising co-occurring disorders.  
However, the mechanism of antidepressants and mood stabilizers for DD remains unclear 
(Maina, Albert, & Bada, 2001; Skelton et al., 2015).   
Cognitive behavioral therapy 
Current treatment for DD also involves cognitive behavioral therapy (CBT), social skills 
training, psychoeducation, and family therapy.  CBT helps the person modify their core beliefs, 
reduce social isolation, and lead to a reduction in conviction regarding the delusion.  Patients will 
also learn how to respond and react to their delusional beliefs and experience improvement in 
social relationships (Fear, 2013).   
Clinicians need to approach the person with a delusion without confronting the delusion 
or validating it.  Ensuring a positive relationship with the patient is crucial with the eventual 
hope that the clinician can gently suggest possible explanations for the delusions and invite them 
to be curious about alternative explanations.  Therapists need to target the reasoning processes 
that underlie the maintenance of the delusional system and address emotional dysfunction (Davis 
et al., 2017; Shea, 2017).  Additionally, CBT with an emphasis on reducing worry may decrease 
in paranoia (Freeman et al., 2015).    
Freeman (2016) suggests that patients with persecutory delusions need to relearn safety 
and enter feared situations after reducing psychological factors.  During therapy, emphasis needs 
to be on establishing knowledge of current safety versus disproving past perceptions or delusions 
in order to reduce worry. The Feeling Safe Program (20 sessions) emphasized this and was found 
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to be effective in which seven of eleven participants no longer meet criteria for a delusion 
(Freeman, 2016). 
A single-blind randomized controlled trial found that cognitive therapy reduced 
psychiatric symptoms in a study of 74 individuals with schizophrenia spectrum disorders not 
taking antipsychotic medications. Of the 74 participants, two had serious adverse events related 
to the CBT trial (one attempted an overdose after therapy and one became a risk to others after 
therapy).  Cognitive therapy also improved social and personal functioning, cognitive 
dimensions of delusional beliefs, and hearing voices.  However, it didn’t reduce the level of 
distress associated with delusional beliefs, voice hearing, self-rated recovery, social anxiety, or 
depression (Morrison et al, 2014).  
Individualized metacognitive training (MCT+) is a new therapy designed to target 
delusional beliefs among people with psychosis.  MCT has been used since 2007 to help patients 
with delusions raise self-awareness of thinking patterns that lead to their delusions.  A recent 
study showed the effectiveness of MCT in patients with schizophrenia with a lasting change of 6 
months.  A randomized clinical trial was conducted among 54 patients with active delusions 
and/or had a schizophrenia spectrum disorder. There were moderate reductions in delusional 
symptom severity with improved insight (Balzan et al., 2018; Liu et al., 2018).  
SlowMo is a digital therapy that helps people with DDs slow down their thinking and 
reduce their fear of harm from others.  It addresses fast thinking, which is believed to contribute 
to developing and maintaining paranoia.  A trial is currently in place to prove its level of efficacy 
in the role of paranoia and set to be completed in 2019 (Garety et al., 2017).   
Behaviorism 
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Behavior learning theories assert that delusions can be treated by use of extinction and 
reconsolidation (Kiren et al., 2009).  Extinction is a behavior principle that occurs only when a 
target behavior no longer has a reinforcing consequence.  If the target behavior is intermittently 
reinforced, it will continue (Miltenberger, 2012).   
If there is an element of associative learning that occurred during delusion formation, 
then extinction may assist to resolve the delusion.  Extinction would result in a decline in 
responding to a certain stimulus related to the delusion.  Prediction error (negative) would lead 
the person to categorize the extinction as different from the original reinforced stimuli or 
situation.  The person would then learn not to expect the associated stimuli in that situation in the 
future.  This would not involve unlearning of the original associated stimuli, but would result in  
a formation of a new association between the extinction situation and absence of the reinforcer.  
Most importantly, extinction experiences will invoke an inhibitory learning process that will 
eventually override the original cue response (original stimuli or reinforcer) in the midbrain 
(Kiren et al., 2009; Miltenberger, 2012).  
Treatment Challenges  
The nature of DD 
The nature of the disorder itself, mistrust of people, lack of evidence for treatment, and 
fear of the consequences of sharing information, i.e. involuntary commitment or police 
involvement pose as challenges in treatment (Shea, 2017; Skelton et al., 2015).  Trust is very 
difficult to obtain among individuals with DD.  A lack of evidence for treatment enables a 
powerful argument against engaging in treatment.  People DD often maintain normal level of 
functioning and often doing have symptoms warranting emergency or forced treatment (Skelton 
et al., 2015).  Further complicating factors is a lack of treatment consensus with regards to what 
TREATMENT CHALLENGES OF DELUSIONAL DISORDERS  17 
 
is the best method of treatment for DD and how to assess patient response to treatments 
(Gonzalez-Rodriguez, 2018).   
Adherence 
People with DDs are currently being viewed under the lens of treatment for schizophrenia 
spectrum disorders.  This is thought be the result of individuals’ reluctance to engage in 
treatment. Measuring adherence to antipsychotic medications is difficult.  A systematic review 
found that 66% of reviewed studies used subjective methods to ascertain adherence to 
medications.  A higher rate of adherence was found in three studies that used objective means to 
measure adherence (plasma serum) resulting in a range of adherence of 92.6%-100%. However, 
adherence was likely attributed to the subjects knowing they were being monitored (Estrada, 
Monreal, Deigo, Labad, & 2018).    
Disagreement on DD 
There is vast disagreement and confusion in the literature about what constitutes a DD as 
well as which co-morbidities are allowed.  There needs to be a different way of classifying this 
disorder as it is neither an affective disorder nor a schizophrenia spectrum disorder (Fear, 2013).  
Kiran and Chaudhury (2009) describe essential criteria of how to distinguish different forms of 
beliefs such as over-valued ideas versus a true delusion.  They believe the criteria for a delusion 
does not necessarily lie in the person’s certainty or conviction of the delusion nor in their 
incorrigibility. Rather, a delusion is determined within the contexts and origins of the patient’s 
own experiences.  In other words, a delusion is an experience rather than a belief or judgement.  
The delusional experience is not an interpretation of meaning, but rather meaning directly 
experienced, i.e. an experience that hasn’t yet had the chance to pass thru rational thought or 
judgement.  There is no interpretation of meaning of the experience.  There is only the 
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experience.  Subsequently, the experience emerges thru a lens of past psychic events and are 
traced back to specific affects, desires, fears (worst case scenarios), and drives, i.e. irrational 
mediums void of a mediation by logic.  The delusion often has overwhelming personal 
significance and is determined by the social, emotional, and cultural background of the patient 
(Kiren et al., 2009).   
Limited strong evidence 
Furthermore, no studies are available to distinguish treatment and efficacy of 
antipsychotics for DDs in older patients (Colijn, Nitta, and Grossberg, 2015).  The only evidence 
available speaking to the relevance of age included people with onset of illness in their middle 
40’s and evaluated in their early 50’s.  This was a longitudinal observational study that found 
that long-acting injectables (either risperidone or paliperidone palmitate) demonstrated greater 
improvement in negative and positive symptoms compared to patients treated with oral 
antipsychotics (Colijn et al., 2015; Gonzalez-Rodriguez et al., 2014b).  
A systematic review sought to determine the effectiveness of medications and 
psychotherapy in comparison to placebo among persons with DD.  The results included limited 
information on specific medication efficacy and high risk of bias.  There was a positive effect for 
CBT with improving social self-esteem, but unknown information about social function.  
Information was also limited with regards to psychotherapy as many clients left therapy early.  
The review concluded that there is limited quality of evidence to for developing treatment 
recommendations for DD and no evidence for improvement in overall functioning (Skelton et al., 
2015). 
Cognitive behavioral therapy is beneficial, but time-consuming and requires many 
resources.  If the individual agrees to engage in therapy, they can often be frustratingly 
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loquacious during sessions.  They have boundless evidence to support their delusions and create 
elaborate methods of refuting any evidence against their belief.  There is no room for 
coincidence, misunderstanding, or different interpretation of the facts.  They also often fail to 
take their medication(s) (Fear, 2013). 
Implications 
Research needs  
In order to make recommendations that are generalizable to people with DD, there needs 
to be high quality research conducted on DD.  There is heavy reliance on case reports and a need 
for high quality randomized trials for DD treatments.  People with DDs should be recruited into 
larger studies among people on a spectrum of psychoses (Fear, 2013; Skelton et al., 2015).   
Improved evidence of the role of serotonin and subgroups of 5-HT3A in fear memory 
regulation is also needed (Davis et al, 2015; Kondo et al., 2013).  Consensus among researchers 
on measuring antipsychotic response and methods used to study treatment adherence in DD 
(Estrada et al., 2018; Gonzalez-Rodriguez et al., 2018).  Furthermore, delusional thoughts 
processes cannot be corrected by medications alone and developing effective and accessible 
psychological interventions is a priority (Fear, 2013; Garety et al., 2017; Liu et al., 2018).  
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